Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management
Launched by WROCLAW MEDICAL UNIVERSITY · Jan 17, 2022
Trial Information
Current as of November 13, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is testing whether injecting a person’s own platelet-rich fibrin (iPRF) into the jaw joint helps people with mild to moderate temporomandibular joint (TMJ) degeneration more than injections of platelet-rich plasma (PRP). It’s a randomized, two-arm trial with about 42 adults aged 18–80. Participants are assigned by chance to receive two injections into the jaw joint, given 30 days apart.
If you join, you’ll have visits on the day of the first injection (D0), the day of the second injection (D30), and about 60 and 120 days after the first injection. Researchers will use MRI/CT scans, measure jaw movement, listen for joint sounds, and ask several questionnaires about pain, jaw function, and quality of life. Eligibility includes being 18–80 years old with mild to moderate TMJ degeneration confirmed by exam and imaging, and you must meet several health criteria to avoid safety risks (for example, you must not have certain serious diseases or recent TMJ treatments). The study is at Wroclaw Medical University in Poland, is currently enrolling, and results are not yet available.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age between 18 and 80 years old
- • mild to moderate degenerative temporomandibular joint disease based on DC/TMD protocol and MRI/CT
- • agreement to take part in the study
- Exclusion Criteria:
- • severe hematologic and/or neurological disorder
- • rheumatoid arthritis
- • septic arthritis
- • polymyalgia rheumatica
- • gout
- • Paget's disease
- • osteonecrosis
- • connective tissue disease
- • malignant disease
- • vasculitis
- • any previous temporomandibular joint (TMJ) invasive treatment
- • any current temporomandibular joint (TMJ) conservative or invasive treatment
- • patients who had used oral, parenteral or intra-articular corticosteroids in the 3 months prior to the first injection
- • previous or current radiotherapy of head and neck
- • pregnancy or lactation
- • presence of severe mental disorders
- • drug and/or alcohol addiction
- • presence of local contraindications for injection therapy
- • patients with needle phobia
- • presence of hypersensitivity to substances to be used in the study
About Wroclaw Medical University
Wrocław Medical University is a prestigious academic institution located in Wrocław, Poland, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in healthcare and biomedical sciences to facilitate innovative research initiatives aimed at improving patient outcomes. With a strong emphasis on ethical practices and regulatory compliance, Wrocław Medical University collaborates with a diverse network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the development of new therapies and enhance the understanding of various medical conditions. Its dedication to scientific excellence and patient safety positions the university as a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wrocław, Poland
Patients applied
Trial Officials
Mieszko Wieckiewicz, Prof.
Study Chair
Wroclaw Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials